Avalo prices $375 million follow-on offering at $17.75 per share

Avalo Therapeutics Inc

Avalo Therapeutics Inc

AVTX

0.00
  • Avalo Therapeutics priced an underwritten public offering of 19,730,000 common shares at USD 17.75 per share.
  • Offering also includes pre-funded warrants to buy 1,400,000 common shares at USD 17.749 per warrant, with a USD 0.001 exercise price.
  • Gross proceeds expected at about USD 375 million, excluding fees and assuming no exercise of underwriters’ option for up to 3,169,500 additional shares; closing expected May 7, 2026.
  • Net proceeds earmarked to advance clinical development of abdakibart through Phase 3 topline data release, with remainder for working capital and general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on May 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.